Stock Takes 18% Hit Based on Confusion
Potential M&A Target Achillion Clarifies Positive HCV Data
Following a weekend poster presentation that confused some investors, Achillion Pharmaceuticals Inc. clarified on Monday that all patients who completed a 24-week regimen involving its hepatitis C virus (HCV) drug ACH-1625 had undetectable levels of HCV RNA – yet the company's stock continued a downward slide throughout the day.